Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed a share repurchase on 13 May 2026 via the Hong Kong Exchange. The company bought back 240,000 H-shares at prices between HKD 3.47 and HKD 3.50, with a volume-weighted average price of HKD 3.48. The total consideration reached approximately HKD 0.84 million.

Following the transaction, the number of issued shares excluding treasury stock fell by 0.0054% to 4.47 billion, while treasury shares increased to 55.13 million. The overall issued share count remained unchanged at 4.52 billion.

The buyback forms part of a mandate approved on 27 May 2025 that authorises the repurchase of up to 451.56 million shares. Cumulative repurchases under this mandate now stand at 48.48 million shares, representing 10.74% of the shares outstanding on the mandate date. In line with listing rules, Weigao Group is subject to a moratorium on new share issues or treasury share sales until 13 June 2026.